The inflammatory Mediator Core serves a central role in the Cystic Fibrosis Research Core Center by providing quick, accurate, and accessible assays of markers and regulators of inflammation necessary for discerning mechanism responsible for CF inflammatory responses and for assessing the efficacy of novel CF therapeutics. The objectives of the Inflammatory Mediator Core are: 1) To perform routine assays of cytokines and other inflammatory mediators on human, mouse, and cultured cell samples provided by Center investigators. The Core will provide prompt, sensitive, reliable, cost effective assays, maintaining high quality control and standardization; 2) To assist investigators in standardizing new assays and to assist laboratory personnel in interpreting results and designing experiments. The Core has experienced remarkable growth in recent years. During the 1996-2000 grant period, the inflammatory mediator core performed 21,818 cytokine assays, while hat number has increased to 48,143 cytokine assays during the current grant period. The Core performs assays of cytokines, eicosanoids, cyclic nucleotides, proteases and protease inhibitors, and metabolic hormones such as leptin on samples from animal models and cultured cells, as well as human samples including BAL, serum, and sputum samples. Currently, the quantitation of the """"""""mediators' is accomplished by primarily by Luminex technology and by ELISA determination of mediator content. Moving forward, the Inflammatory Mediator Core will become a multifaceted facility providing not only the fundamental quantitation of cytokines, chemokines and eicosanoids, but also will incorporate services directed toward understanding gene expression, cell phenotype and cell-cell communication to accommodate more mechanistic-driven research within the Center. These new directions will provide investigators with not only a phenomenological quantification of static mediator content, but will also provide information regarding regulation and functional interactions. These new services will compliment exisiting Core assays and are projected to contribute to further expansion and utilization of the Core in the next grant period.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK027651-25
Application #
7638481
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
25
Fiscal Year
2008
Total Cost
$256,156
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Lai, Nicola; M Kummitha, China; Rosca, Mariana G et al. (2018) Isolation of mitochondrial subpopulations from skeletal muscle: Optimizing recovery and preserving integrity. Acta Physiol (Oxf) :e13182
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
Darrah, Rebecca; Nelson, Rebecca; Damato, Elizabeth G et al. (2016) Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biol Res Nurs 18:498-504
VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9
VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790
Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42
Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Rymut, Sharon M; Kampman, Claire M; Corey, Deborah A et al. (2016) Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 311:L317-27
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87

Showing the most recent 10 out of 445 publications